

# Autism Gene Variants Disrupt Enteric Neuron Migration and Cause Gastrointestinal Dysmotility

Kate E. McCluskey<sup>1</sup>, Katherine M. Stovell<sup>1</sup>, Karen Law<sup>1</sup>, Elina Kostyanovskaya<sup>1</sup>, James Schmidt<sup>1</sup>, Cameron R.T. Exner<sup>1</sup>, Jeanselle Dea<sup>1</sup>, Elise Brimble<sup>2</sup>, Matthew W. State<sup>1</sup>, A. Jeremy Willsey<sup>1</sup>, Helen Rankin Willsey<sup>1,3\*</sup>

<sup>1</sup>Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

<sup>2</sup>Citizen, San Francisco, CA

<sup>3</sup>Chan Zuckerberg Biohub – San Francisco, San Francisco, CA

## Corresponding author:

Helen Rankin Willsey,

<sup>1</sup>Department of Psychiatry and Behavioral Sciences, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA Chan Zuckerberg Biohub – San Francisco, San Francisco, CA

**Received Date:** 01 April 2024

**Accepted Date:** 16 April 2024

**Published Date:** 22 April 2024

## Citation:

Helen Rankin Willsey. Autism gene variants disrupt enteric neuron migration and cause gastrointestinal dysmotility. Japanese Journal of Gastrointestinal 2024.

## 1. Abstract

The biological basis of the well-established comorbidity between severe gastrointestinal symptoms and autism spectrum disorders is yet unknown. By examining these genes within the framework of the gastrointestinal system, it is possible to uncover convergent, underlying biology that may be responsible for the identification of high-confidence large-effect autism risk genes. Here, we demonstrate that the expression of these genes is enriched in human prenatal gut neurons and their migrating progenitors, implying that pathogenic mutations linked to autism may interfere with the formation and/or function of these neurons, resulting in gastrointestinal dysfunction. Here, we report the frequency of gastrointestinal problems in individuals who have large-effect variations in sixteen of these genes. Dysmotility is highlighted, which is consistent with possible failure of the enteric nervous system. We specifically target five of these using the highthroughput diploid frog *Xenopus tropicalis*

## 2. INTRODUCTION

The neurodevelopmental diseases known as autism spectrum disorders

(ASD) are characterized by atypical social relationships, recurring acts, and constrained interests<sup>1</sup>. Gastrointestinal (GI) distress is one of the most common and debilitating comorbidities of Autism Spectrum Disorder (ASD). It typically manifests as symptoms of gastric motility such as constipation, diarrhea, or abdominal pain<sup>2-4</sup>. Even though this comorbidity is well-established, the underlying molecular pathways are still unclear. The identification of genes associated with high-confidence (hc), large-effect autism has made it possible to investigate these genes in vivo and determine the biological causes of this co-occurrence. The development of neural progenitor cells in the central nervous system has been demonstrated to be regulated by hcASD risk genes 6–13, supporting the theory that these genes may also play a role in the development of the enteric nervous system (ENS), which produces the neurons that regulate the gastrointestinal system. In fact, the function of CHD8, one of the first large-effect autism genes discovered, has been clarified in zebrafish, where *chd8* disruption resulted in decreased enteric neuron colonization into the stomach as well as gut dysmotility<sup>14</sup>. It has repeatedly been demonstrated that the expression of autism genes is enriched in adult human enteric neurons, which regulate stomach motility. Taken together, these data suggest that aberrant ENS development could be the cause of the observed comorbidity.

## 3. Results

The expression of the hcASD gene is more abundant in enteric neurons and their precursors. Previous research has demonstrated an enrichment of hcASD gene expression in mature human enteric neurons<sup>15</sup>. We used scRNA sequencing data from various points in the human fetal gut development process to evaluate the expression of the hcASD gene in this tissue during development<sup>26</sup>. In the data set, all 252 hcASD genes with an FDR < 0.15 were expressed. The average expression of these genes and their relative expression enrichment across cell types were determined using Module Score Analysis (AddModuleScore, Seurat R Package) in comparison to a comparably expressed random control geneset (Fig. S1A-B). When compared to all other cell types, enteric neurons and their progenitors, enteric neural crest-derived cells (ENCCs), had a much greater hcASD gene expression enrichment.

## 4. DISCUSSION

Although the co-occurrence of GI problems and autism is well-established<sup>2</sup>, the molecular processes underlying this comorbidity are still unknown. Here we record how often GI problems are in people with hcASD gene variations, emphasizing constipation as a sign of GI dysmotility. Several hcASD genes have been demonstrated by our lab and others to regulate neuronal development in the central nervous

# Japanese Journal of Gastrointestinal

system<sup>6–13</sup>. This has led us to wonder if these genes also play a role in the development of the ENS. We consistently see that during human embryonic development, enteric neurons and their migratory progenitor cells have higher levels of hcASD gene expression. Thus, we deploy a vertebrate *in vivo* model to individually disrupt five hcASD genes with different functional annotations (neurotransmission, chromatin control, kinase) in order to explore this notion. For each, we find aberrant ENCC migration, which raises the possibility that GI dysmotility in ASD is caused by atypical ENCC migration. As we look more closely at *Dyrk1a*'s function in gut motility, we find that when *Dyrk1a* is disrupted, excretion decreases but can be increased again when acutely exposed to serotonergic signaling agonists. This study contributes to the expanding body of research indicating that variations in ASD genes disrupt the development of the ENS<sup>3,50</sup>. This is in line with studies on *CHD8*<sup>14</sup> in zebrafish and *FOXP1*<sup>15</sup> and *PTEN*<sup>52</sup> in mice. Although the gut neuron number 53 was not significantly altered in a fish investigation of *SHANK3*, the researchers did uncover impaired serotonergic transmission in the gut, which is consistent with our findings that regulating serotonin signaling may be a viable therapeutic approach. In fact, since serotonin signaling plays a well-established function in gut motility<sup>44–47</sup>, addressing GI problems in the context of ASD may benefit from a wider exploration of this pathway. Further, important concerns include how variations in the ASD gene impact the quantity, differentiation, structure, appearance, and activity of enteric neurons in mature animals. Given that we have shown a significant loss of function for these genes and that individuals carrying pathogenic mutations in these genes are heterozygous, the impact of gene dosage on these parameters will undoubtedly play a significant role in the future.

## 5. MATERIALS AND METHODS

### Analysis of Ciitizen® Patient Data and Simons Searchlight

The UCSF IRB office, IRB#23-39-079, decided that research using data from the Simons Foundation Autism Research Initiative (SFARI), the Simons Collection (Searchlight), and Ciitizen® medical records was not considered research involving human participants. GI data from afflicted individuals and unaffected families was accessible via the Simons Searchlight Single Gene Dataset v8.0. Every family with any genetic variation in a hcASD gene—defined by Fu et al. 2022<sup>5</sup> with an FDR < 0.1—was included in the analysis. Additionally, patient GI data was retrieved from Ciitizen®. Individuals who had a genetic variation categorized as “pathogenic,” “likely pathogenic,” or “variant of uncertain significance” on their genetic report were included in the study. People having “benign” mutations in one of the hcASD genes were not included. People that possess a Both a “pathogenic” mutation in a non-ASD gene and a “variant of uncertain significance” in a hcASD gene were both ruled out. Using Prism (v.10.1.1), data analysis and visualization were carried out. scRNA-sequencing study and enrichment scoring in the human prenatal gut first, Cell Ranger (GRCh38) was used to process the scRNA-seq FASTQ data of the human fetal gut (ArrayExpress: E-MTAB-948926). We read the gene-barcode matrix outputs of all samples using the normal Seurat analysis pipeline. We then removed low-quality cells with >10%

mitochondrial counts and unique feature counts over 2,500 or less than 200, leaving 39,095 cells. The gene-barcode matrix was then normalized using the LogNormalize technique, which multiplied by the default scale factor (10,000) and normalized each cell by total expression. 2,000

Each sample's highly variable genes were found using the FindVariableFeatures function, and all samples were then integrated using the IntegrateData method to create a single Seurat object for further analysis. The integrated object was subsequently scaled, and dimensions reduction was achieved using Principal Component Analysis. The object's cell clusters were computed using FindNeighbors and FindClusters. In order to complete cell annotations, gene markers from Elmentaite et al. 2020<sup>57</sup> were used to identify cell clusters in addition to ENCC indicators (*SOX10*, *FOXD3*, *PHOX2B*) and enteric neuron markers (*TUBB3*, *ELAVL4*, *RET*). The 252 hcASD genes from Fu et al. 2022 were subjected to the AddModuleScore function in order to evaluate the enrichment of these genes. The results were compared with a control geneset that had equal average expression in all cells. Every cell was given a module score and was then categorized using the previously mentioned cell annotation method. When a cell expressed the control geneset higher than the hcASD genes, it scored less than 0, but when a cell expressed the hcASD genes higher than the control geneset, it scored more than 0. The cells were then categorized using the aforementioned clustering into three groups: enteric neurons, ENCCs, and Non-ENS cells. Next, we used a Kruskal-Wallis test, Wilcoxon rank-sum testing, and Benjamini-Hochberg adjustment for multiple comparisons to determine if ENCCs and enteric neurons had hcASD gene expression enrichment values that were substantially greater than those of any other cell. Using VlnPlot, the enrichment of these genes in each cluster or group was shown.

### Acknowledgements

the previous Simons VIP Consortium is now known as the Simons Searchlight Consortium. We are grateful for having access to SFARI Base's Simons Searchlight phenotyping data. We are grateful to Hasan Alkhalil for his coding discussions, Nolan Wong, Louie Ramos, and UCSF LARC for their animal care, Ashley Clement, Gigi Lopez, Sonia Lopez, and Linda Chow for their administrative support, and Juan Arbelaez and Ethel Bader for lab maintenance and support. Without daily access to the Xenopus community resource Xenbase (RRID:SCR\_003280) and the knowledge and frog resources provided by the National Xenopus Resource (RRID:SCR\_013731), this work would not be possible.

### Funding

This work was supported by a grant from the National Institutes of Mental Health (U01MH115747 to A.J.W and M.W.S) and an investigator award from the Chan Zuckerberg Biohub - San Francisco (to H.R.W.).

### References

1. Hughes, M. M. et al. The Prevalence and Characteristics of Children

- With Profound Autism, 15 Sites, United States, 2000-2016. Public Health Rep. 138, 971–980 (2023).
2. McElhanon, B. O., McCracken, C., Karpen, S. & Sharp, W. G. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. *Pediatrics* 133, 872–883 (2014).
  3. Wang, X. et al. The enteric nervous system deficits in autism spectrum disorder. *Front. Neurosci.* 17, 1101071 (2023).
  4. Wasilewska, J. & Klukowski, M. Gastrointestinal symptoms and autism spectrum disorder: links and risks – a possible new overlap syndrome. *Pediatric Health, Medicine and Therapeutics* 6, 153–166 (2015).
  5. Fu, J. M. et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. *Nat. Genet.* 54, 1320–1331 (2022).
  6. Willsey, H. R. et al. Parallel in vivo analysis of large-effect autism genes implicates cortical neurogenesis and estrogen in risk and resilience. *Neuron* 109, 788–804.e8 (2021).
  7. Satterstrom, F. K. et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. *Cell* 180, 568– 584.e23 (2020).
  8. Li, M. et al. Integrative functional genomic analysis of human brain development and neuropsychiatric risks. *Science* 362, (2018).
  9. Polioudakis, D. et al. A Single-Cell Transcriptomic Atlas of Human Neocortical Development during Mid-gestation. *Neuron* 103, 785–801.e8 (2019).
  10. Fan, X. et al. Spatial transcriptomic survey of human embryonic cerebral cortex by single-cell RNA-seq analysis. *Cell Res.* 28, 730–745 (2018).
  11. Willsey, A. J. et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. *Cell* 155, 997–1007 (2013).
  12. Weinschutz Mendes, H. et al. High-throughput functional analysis of autism genes in zebrafish identifies convergence in dopaminergic and neuroimmune pathways. *Cell Rep.* 42, 112243 (2023).
  13. Birtele, M. et al. Non-synaptic function of the autism spectrum disorder-associated gene SYNGAP1 in cortical neurogenesis. *Nat. Neurosci.* 26, 2090–2103 (2023).
  14. Bernier, R. et al. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell* 158, 263–276 (2014).
  15. Drokhlyansky, E. et al. The Human and Mouse Enteric Nervous System at Single-Cell